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Genetic treatments of renal ciliopathies leading to cystic kidney
disease would provide a real advance in current therapies. Muta-
tions in CEP290 underlie a ciliopathy called Joubert syndrome (JBTS).
Human disease phenotypes include cerebral, retinal, and renal dis-
ease, which typically progresses to end stage renal failure (ESRF)
within the first two decades of life. While currently incurable, there
is often a period of years between diagnosis and ESRF that provides
a potential window for therapeutic intervention. By studying pa-
tient biopsies, patient-derived kidney cells, and a mouse model, we
identify abnormal elongation of primary cilia as a key pathophysi-
ological feature of CEP290-associated JBTS and show that antisense
oligonucleotide (ASO)-induced splicing of the mutated exon (41,
G1890*) restores protein expression in patient cells. We demon-
strate that ASO-induced splicing leading to exon skipping is toler-
ated, resulting in correct localization of CEP290 protein to the ciliary
transition zone, and restoration of normal cilia length in patient
kidney cells. Using a gene trap Cep290 mouse model of JBTS, we
show that systemic ASO treatment can reduce the cystic burden of
diseased kidneys in vivo. These findings indicate that ASO treat-
ment may represent a promising therapeutic approach for kidney
disease in CEP290-associated ciliopathy syndromes.
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Joubert syndrome (JBTS) is an archetypal ciliopathy syndrome,characterized by multisystem involvement, including retinal
dystrophy and degeneration, cerebellar vermis aplasia, and
nephronophthisis. JBTS is incurable and nephronophthisis rep-
resents the major cause of pediatric renal failure (1). Studying the
molecular genetics of JBTS has led to the discovery of numerous
genes underlying this disorder, which all encode protein products
associated with the primary cilium. CEP290 is the most common
genetic cause of JBTS with a cerebello-retinal-renal phenotype
(2). Mutations in CEP290may give rise to additional phenotypes as
part of a disease spectrum including Leber congenital amaurosis
(LCA), Senior Loken syndrome, Meckel Gruber syndrome, and
Bardet Biedl syndrome (3–6). The CEP290 gene has 54 exons that
encode a protein located at the transition zone of the primary cilium
where it is thought to play a gatekeeper role in the entry and exit of
proteins from the ciliary axoneme (7). Ciliary signaling mechanisms
such as the Sonic hedgehog (SHH) pathway have been shown to be
disrupted in both mouse models of JBTS and primary patient renal
epithelial cells; pharmacological manipulation of SHH signaling has
been shown to ameliorate features of the disease, such as primary
cilia defects (8, 9). However, such pharmacological interventions do
not correct the primary lesion and, particularly in the case of
modulation of SHH signaling, carry a risk of unwanted side effects.
Recent studies have suggested alternative therapeutic strate-
gies for ciliopathies that directly correct the genetic lesion, in
particular targeting CEP290 mutations in LCA (10). The most
common cause of LCA is an intronic mutation that creates a splice
donor site and a pseudoexon, disrupting the CEP290 transcript
(11). Treatment with a splice-blocking antisense oligonucleotide
(ASO) was able to restore the normal transcript in both patient
cell lines and a mouse model of LCA (10). The majority of
CEP290 mutations causing JBTS are within the coding sequence,
which is more suited to gene replacement therapy. However, the
size of the gene (54 exons) and its protein product (290 kDa) pose
a considerable challenge for conventional, viral-based, gene re-
placement therapies, although lentiviral vector delivery of full-
length CEP290 has been used successfully in patient fibroblast
cells (12). Following a report of a patient with a mild LCA phe-
notype associated with nonsense-mediated alternative splicing of
CEP290 (11), an extensive study of endogenous (wild-type)
splicing revealed widespread, low-level alternative splicing that
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could be modeled to predict genetic pleiotropy associated with
CEP290 mutations (13). Indeed, confirming this hypothesis,
endogenous basal exon skipping and nonsense-associated al-
tered splicing has been documented in patient fibroblasts with
nonsense mutations in CEP290 with mild retinal phenotypes
(14). These observations are reminiscent of the Duchenne/
Becker muscular dystrophy paradigm (15), which responds to
targeted exon skipping therapies (16, 17). Given that most of the
CEP290 protein consists of repeated coiled-coil domains, often
encoded by a single exon, CEP290 seems an ideal candidate for
ASO-mediated exon skipping therapy.
Results
Clinical and Genetic Investigations.Here we describe a 14 y old boy
(JBTS-AA) from consanguineous parents (Fig. 1A) affected with
JBTS. He initially presented with congenital ptosis and visual
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Fig. 1. Clinical phenotype, molecular genetics, and primary cilia defects in human urine-derived renal epithelial cells from a Joubert syndrome patient. (A)
Pedigree diagram showing single affected male, JBTS-AA (squares, males; circles, females). (B) Renal ultrasound scan of JBTS-AA showing minor cystic change
within the kidney (arrowed) and loss of corticomedullary differentiation consistent with a diagnosis of nephronophthisis. (C) MRI scan of JBTS-AA showing a
molar tooth sign (arrowed) with cerebellar vermis aplasia and elongated superior cerebellar peduncles. (D) Sequence chromatograms showing homozygous
change in CEP290 c.5668G > T; p.G1890* segregating from parental DNA (father’s chromatogram is shown). (E) SMART Domain structure of WT CEP290
protein (2,479 amino acids) predicts multiple coiled-coil domains (show as blue bars). The truncated protein CEP290 G1890* results in loss of C-terminal coiled-
coil domains. (F) Western blotting of protein from human urine-derived renal epithelial cells showing loss of full-length CEP290 protein in JBTS-AA. Blots were
probed with a CEP290 antibody directed at the C terminus of CEP290, with GAPDH shown as a loading control. (G) Wild-type (WT) and (H) patient (JBTS-AA)
hURECs imaged under high-power immunofluorescence using anti-ARL13B (green) to identify ciliary membrane. (Scale bar: 5 μm.) (I) Quantification of ciliary
length in cells grown in serum-free medium for 48 h, measured by immunofluorescence imaging (WT, n = 55, JBTS-AA, n = 222; ***P < 0.0001, unpaired
t test). (J) Wild-type (WT) and (K) patient (JBTS-AA) hURECs seen under scanning EM reveals abnormally long cilia in patient cells after 48 h serum starvation
(Scale bar: 2 μm.). (L) Quantification of increase in cilia length (WT, n = 16, JBTS-AA, n = 10; *P < 0.05, unpaired t test).
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failure secondary to an early onset retinal degeneration (SI Ap-
pendix, Fig. S1) and subsequently developed ataxia and signifi-
cant renal impairment (Table 1). Clinical investigations revealed
hyperechogenic kidneys showing cystic change and loss of corti-
comedullary differentiation (Fig. 1B), consistent with a diagnosis of
nephronophthisis, and a “molar tooth” sign on brain MRI (Fig.
1C) which is due to cerebellar vermis aplasia and is the defining
feature of JBTS. Molecular genetic investigations in JBTS-AA
confirmed a homozygous nucleotide substitution leading to a
stop codon (c.5668G > T; p.G1890*) in exon 41 of CEP290 (Fig.
1D). This mutation is predicted to lead to a truncated CEP290
protein lacking numerous C-terminal coiled-coil domains (Fig. 1E).
Phenotyping Using Primary Renal Epithelial Cells. To characterize
the cellular and molecular consequences of this mutation, we de-
rived primary, nontransformed human urine-derived renal epithelial
cells (hURECs) from patient JBTS-AA and age/sex matched con-
trols (WT). Western blotting, using a CEP290 C-terminal antibody,
confirmed an almost complete absence of full-length CEP290 pro-
tein (Fig. 1F) from patient hURECs. Immunofluorescence analy-
sis of cilia structure revealed elongated primary cilia on patient
hURECs (JBTS-AA) compared with control (WT) cells (Fig. 1G–I).
This was confirmed by scanning electron microscopy (Fig. 1 J–L). In
terms of percentage ciliation rates in hURECs, there was no dif-
ference between wild-type and JBTS-AA cells (SI Appendix, Fig.
S2). We have previously described an elongated cilia phenotype
in hURECs derived from an unrelated JBTS patient harboring
CEP290mutations (9), suggesting abnormally long primary cilia may
be a common, renal feature of JBTS. To investigate this further, we
carried out immunofluorescence analysis of cilia structure in two
further (unrelated) JBTS patients with CEP290 mutations and
kidney failure (SI Appendix, Table S1). Immunofluorescence stain-
ing of renal biopsies for acetylated tubulin and ARL13B revealed
the presence of elongated and tortuous primary cilia in both patients
compared with normal kidney (SI Appendix, Fig. S3) confirming that
the elongated primary cilia found on patient hURECs accurately
reflect the phenotype observed in vivo. It is intriguing to note that
elongated cilia have also been found in a wide range of other cili-
opathy models including: Bbs-4 null mice (18), jckmice (19), Meckel
syndrome (20), Kif7 mutated cells (21), and JBTS secondary to
KIAA0556 mutations (22), suggesting elongated primary cilia may
be a widespread feature of ciliopathies in general and that correc-
tion of this phenotype attenuates cystic kidney disease (23).
Targeted Exon Skipping of CE290 Rescues Phenotype in Primary Renal
Epithelial Cells. Exon 41 of CEP290 is 123 nucleotides in length and
encodes a single, discrete, coiled-coil domain of the protein (SI
Appendix, Fig. S4). Consequently, a splice-blocking ASO targeted to
the splice donor site of exon 41 would be predicted to induce
skipping of exon 41, while maintaining the correct reading frame, to
produce a transcript encoding a near full-length protein of 2,438
amino acids (286 KDa) that contains a normal C terminus and is
lacking only a single coiled-coil domain (SI Appendix, Fig. S4). To
test the functionality of the splice blocking ASO, we carried out
RT-PCR analysis of the CEP290 transcript from hURECs and
confirmed efficient ASO-induced alternative splicing, skipping exon
41 (Fig. 2A). In the absence of any available N-terminal CEP290
antibodies, quantitative RT-PCR of the CEP290 transcript targeted
to exons 6–7, upstream of the mutation in JBTS-AA, showed that
CEP290 expression levels in JBTS-AA hURECs are reduced to
∼20% of wild-type levels, suggesting degradation of the mutant
mRNA transcript; levels of the transcript are rescued following
ASO-induced splicing (SI Appendix, Fig. S5A). Furthermore, we
observed restoration of protein expression by Western blot in ASO-
treated JBTS-AA hURECs, with near wild-type levels of protein
detectable with the C-terminal CEP290 antibody at 24 h post
treatment, which persisted for 96 h (Fig. 2B). In addition to the
structural ciliary changes observed, JBTS-AA hURECS showed an
increase in SHH levels (∼fourfold) indicating dysregulation of cili-
ary signaling. Transcript levels of SHH were, however, not fully
rescued by ASO treatment (SI Appendix, Fig. S5B).
Despite lacking a single coiled-coil domain encoded by exon 41,
the near full-length CEP290 protein correctly localized to the tran-
sition zone in ASO-treated JBTS-AA hURECs (SI Appendix, Fig.
S6); this provides evidence that the removal of exon 41 in CEP290
does not affect protein localization. Given the correct localization of
the restored protein, lacking a single coiled-coil domain, we inves-
tigated whether this could ameliorate the phenotype of JBTS-AA
hURECs. Primary cilia were analyzed using fluorescence microscopy
directed at ARL13B and a significant reduction in the length of
JBTS-AA primary cilia, equivalent to wild-type cilia was observed
after 48 h (Fig. 2 C and D); this was also confirmed by scanning
electron microscopy (Fig. 2 E and F). It is noteworthy that the re-
duction in cilia length is dramatic and significant even at 24 h, in-
dicating a rapid response to ASO treatment. This extends our
previous findings, that pharmacological treatments can reduce cilia
length in JBTS hURECs (9), and provides evidence to suggest that
this phenotype, which relies upon the continued presence of the
mutation, is reversible. Importantly, ASO treatment of wild-type
control hURECs had no effect on the length of the primary cil-
ium, suggesting that the absence of the coiled-coil domain encoded
by exon 41 can be tolerated.
Targeted Exon Skipping of Cep290 in Vivo Rescues Ciliary and Cystic
Kidney Disease Phenotypes. Having shown a positive effect of ASO
treatment on primary, nontransformed patient kidney cells ex vivo,
Table 1. Molecular and clinical characteristics of affected patient (JBTS-AA)
Characteristics JBTS-AA
Ethnicity and consanguinity Pakistani, parents first cousins, segregation confirmed
Renal ultrasound scan
findings
Increased echogenicity, corticomedullary cysts, loss of corticomedullary
differentiation
Kidney function Chronic kidney disease stage 3, creatinine 1.91 mg/dL (aged 14 y)
Ocular symptoms (age of onset, y) Congenital ptosis (1 mo) Early onset retinal degeneration initially diagnosed
with visual failure (2 mo)
Central nervous symptoms Ataxia, cerebellar vermis aplasia/hypoplasia with “molar tooth sign” on brain MRI
Nucleotide alterations Homozygous c.5668G > T (exon 41)
Alteration in coding
sequence
Homozygous Gly1890*
Reference sequence NM_025114
SNP ID rs137852832
ExAC allele frequency 0.0001432
*Stop codon
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we wished to determine whether a similar strategy could be applied
in vivo. The most faithful model of JBTS described to date is the
Cep290Gt(CC0582)Wtsi mouse line (which we will refer to as Cep290Gt,
previously reported asCep290LacZ) that presents with a renal-retinal-
brain phenotype caused by insertion of a “gene trap” within Cep290
after exon 25 (8). As the Cep290Gt mice were produced from em-
bryonic stem (ES) cells containing an intronic splice acceptor/β-
galactosidase/neomycin phosphotransferase (SA-IRES-βGEO) “gene
trap” cassette (3,975 bp), we designed a new oligonucleotide to block
the splice acceptor of the gene trap cassette (vivo-ASOGt) to restore
full-length Cep290 transcript and protein (SI Appendix, Fig. S7). As
proof of concept, treatment of immortalized kidney cells derived
from homozygous Cep290Gt/Gt mice with vivo-ASOGt resulted in a
modest restoration of correct splicing between exons 25 and 26, with
a concomitant decrease in exon 25 splicing into SA-IRES-βGEO,
and a return of a full-length Cep290 protein detected by Western
blotting using a C-terminal Cep290 antibody (SI Appendix, Fig. S7).
In contrast to ASO treatment of JBTS-AA hURECs, wild-type
levels of transcript/protein were not achieved in the transformed
mouse cell line following vivo-ASOGt treatment. RT-PCR analysis
with a panel of primers located across the SA-IRES-βGEO cassette
suggests that we do not see complete restoration of wild-type tran-
script levels (SI Appendix, Fig. S7), possibly due to the presence of
cryptic splice sites within the SA-IRES-βGEO cassette (24, 25).
However, given that CEP290 is not haploinsufficient and it has been
reported that small fragments of CEP290 can ameliorate LCA (26),
we reasoned that even subwild-type levels of protein may be bene-
ficial. Therefore, we proceeded to investigate the potential effects of
a modest restoration of full-length protein in vivo, in Cep290Gt/Gt
mice. Systemic administration of vivo-ASOGt was carried out via a
series of i.v. injections over 10 d. RT-PCR analysis and sequencing
of whole kidney RNA revealed correctly spliced transcripts (Fig. 3A
and SI Appendix, Fig. S8), consistent with splicing from exon 25 to
exon 26, skipping SA-IRES-βGEO. Full-length Cep290 protein was
detected by aWestern blot of whole kidney extracts using C-terminal
Cep290 antibody (Fig. 3B) indicating that vivo-ASOGt was capable
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Fig. 2. ASO-induced exon skipping restores CEP290 protein expression and rescues cilia defects in patient hURECs. (A) Gene expression analysis using RT-PCR
of hURECs obtained from patient JBTS-AA. Lane 1 demonstrates CEP290 (predicted 520 bp) expression in untreated cells. Lane 2 shows RT-PCR products
obtained after treatment with 1 μm ASO directed toward exon 41 splice-junction. ASO-mediated exon skipping leads to a shorter CEP290 mRNA transcript
(predicted product size of 397 bp). (B) CEP290 exon 41 skipping induced by ASO of JBTS-AA hURECs demonstrates the rescue of CEP290 protein translation.
WT hURECs protein lysates demonstrate the presence of full-length CEP290 protein (290 kDa), which was not adversely affected by ASO treatment. JBTS-AA
hURECs protein lysates show a near absence of full-length protein. JBTS-AA ASO-treated hURECs show rescue of near full-length CEP290 protein translation at
24 h post treatment, which persists for 96 h. BETA-ACTIN (42 kDa) serves as loading control. (C) Immunofluorescence (IF) microscopy of wild-type hURECs,
untreated JBTS-AA hURECs, and JBTS-AA hURECs treated with ASO to induce exon skipping of exon 41 rescues the phenotype of long cilia. DAPI- blue
(Nuclei), Green - ARL13B (Ciliary membrane). (Scale bar: 5 μm.) (D) IF quantification of the cilia length in JBTS-AA hURECs followed by treatment with ASO.
Cilia length was quantified after treatment with 1 μM ASO at 24 h and 48 h. The mean cilia length measured for untreated JBTS-AA cilia (n = 24) was 8.36 μm
(detected using ARL13B antibodies). The mean cilia length after treatment with 1 μM ASO for 24 h (n = 50) was 4.56 μm and after treatment for 48 h (n = 50)
was 4.02 μm. The mean cilia length of WT hURECs cilia (n = 49) before treatment was 3.96 μm and after treatment with 1 μM ASO for 48 h (n = 50) was 3.87 μm.
Data are shown as scattergrams with mean shown. *P < 0.0001 determined by one-way ANOVA. (E) Scanning electron microscopy of hURECs cilia in WT, un-
treated JBTS-AA, and JBTS-AA treated with ASO and imaged at 48 h. (Scale bar: 2 μm.) (F) Electron microscopy (EM) quantification of the cilia length in WT, JBTS-
AA, and JBS-AA+ ASO treated hURECs rescued by treatment with ASO. The mean cilia lengths were: WT hURECs 4.8 μm, JBTS-AA 6.74 μm, and JBTS-AA + ASO
3.78 μm. Data are shown as scattergrams with mean indicated.*P < 0.05 and **P < 0.01, one-way ANOVA. n = 10 cilia for each group. n.s., not significant.
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of inducing skipping of SA-IRES-βGEO in kidney, in vivo. Whole
murine kidney tissue protein extract was used to assess the response
of ciliary signaling molecules. Compared with wild-type controls,
Cep290Gt/Gt kidneys had increased Shh signaling, as demonstrated by
a rise in the Gli3 activator to repressor ratio that was partially
restored by treatment with vivo-ASOGt (SI Appendix, Fig. S5 C and
D). Immunofluorescence analysis revealed an increase in the length
of primary cilia (Arl13b staining) in cortical collecting ducts
(aquaporin-2 staining) in homozygous Cep290Gt/Gt mice compared
with wild-type littermates (Fig. 3 C and D), highlighting a further
similarity between the Cep290Gt mouse model and JBTS patients
with CEP290mutations (SI Appendix, Fig. S2). This increase in cilia
length of cortical collecting duct cells could be rescued by ∼50% by
systemic vivo-ASOGt treatment, similar to the 24 h ASO treatment
of JBTS-AA hURECs. Having shown full-length protein and a
shortening of the abnormally long primary cilia following vivo-
ASOGt treatment, we carried out quantitative assessment of cys-
tic burden in vivo-ASOGt treated and untreated Cep290Gt/Gt kid-
neys. Remarkably, vivo-ASOGt treatment resulted in a striking and
significant improvement in cystic index (Fig. 3 E and F) of 37%,
indicating that measurable therapeutic benefit can be achieved
in vivo by relatively modest levels of ASO-induced splice blocking.
Discussion
We have shown that in human renal epithelial cells from a pa-
tient with JBTS secondary to a nonsense mutation in exon 41 of
CEP290, ASO-mediated exon skipping can ameliorate the ciliary
phenotype and restore localization of a near full-length CEP290
protein to the base of the cilium. We have then validated this
approach in vivo, by using a different ASO targeting strategy to
promote alternate splicing of a murine gene trap insertion within
intron 25 of Cep290, thereby rescuing, in part, full-length Cep290
transcript and protein to achieve a phenotypic rescue of renal
ciliary length in vivo as well as the cystic kidney disease. The ob-
served phenotypic changes in murine and human cells, as well as
in mouse kidney tissue following treatment with two completely
different ASOs indicate that the observed effects are specific, and
result from the restoration of CEP290/Cep290.
Overall, these data have several important implications. Firstly,
systemic delivery of ASOs can ameliorate kidney pathology in a
whole animal model. In addition, ASOs can rescue disease phe-
notypes after disease has become established in both JBTS patient-
derived cells and an animal model, confirming the indications from
pharmacological treatments that the cystic kidney disease is re-
versible. Finally, ASO-mediated exon skipping is tolerated at
the level of protein localization, as the removal of a coiled-coil
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Fig. 3. In vivo systemic ASO treatment restores Cep290 protein expression and reduces cystic burden in a JBTS mouse model. (A) RT-PCR of Cep290 from
murine kidney mRNA. RT-PCR products spanning exons 25–27 are shown from kidneys of wild-type (WT), heterozygous Cep290Gt/+ (HET), and homozygous
Cep290Gt/Gt (HOM) mice. Almost no product is observed when the gene trap is present homozygously. Treatment with vivo-ASOGt of HOM mice increases the
amount of wild-type Cep290 transcript. Hprt is shown as a control. (B) Western blot showing Cep290 protein isolated from WT, HOM, and HOM mice treated
with vivo-ASOGt to induce skipping of the gene trap. The level of protein in homozygous animals increases in the presence of the ASOGt treatment. GAPDH
(37 kDa) is shown as loading control. (C ) Immunofluorescence imaging of renal primary cilia within cortical collecting ducts in WT, HOM, and HOM mice
treated with vivo-ASOGt. Cilia are stained with Arl13b (green), collecting ducts are identified using aquaporin-2 (magenta), and nuclei are stained with
DAPI (blue). Images are taken from samples with median values of their respective groups. (Scale bar: 10 μm.) (D) Quantification of mean primary cilia
length from renal tissues of WT (n = 3), HOM (n = 4), and HOM + ASOGt treated mice (n = 7). Mean number of cilia measured in each animal = 97. (*P <
0.05, one-way ANOVA). (E ) Hematoxylin and eosin staining of untreated HOM and vivo-ASOGt treated HOM mice. Images are taken from samples with
median values of their respective groups. (Scale bar: 1 mm.) (F ) Quantification of the cystic index of untreated HOM (n = 5) and vivo-ASOGt treated HOM
mice (n = 7) at 42 d of age. The mean cystic index is reduced from 0.011 in untreated animals to 0.0069 in animals treated with vivo-ASOGt (*P < 0.05,
unpaired t test).
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domain does not result in the mislocalization of the CEP290 pro-
tein. Given that many CEP290 mutations cluster in the C-terminal
coiled-coil-rich region and are potentially skippable (SI Appendix,
Fig. S9), it is tempting to speculate that these mutations may also be
amenable to ASO-mediated therapy.
One limitation of this study is that despite G1890* being one
of the most common mutations, we have not extended our hu-
man studies to other skippable exons in CEP290. Here true
personalized medicine approaches, using patient-derived cells, such
as we have used with patient JBTS-AA, will be required to de-
termine if exon skipping of alternate exons, which may contain
more crucial functional domains than exon 41, are possible. The
direct consequences of skipping exons within the CEP290 gene
require testing in both ex vivo and in vivo systems. A Cep290mouse
model, mimicking the human G1890* mutation, would be required
to determine fully the effects of ASO-mediated exon skipping in
both kidney and extrarenal tissues. Given the ease of access for
subretinal injections, to date there has been a focus on ASO-based
therapies for human retinal disease, including CEP290-associated
LCA (10, 27). As our work has shown, systemic delivery of ASOs is
possible and seems to ameliorate kidney disease; this needs to be
assessed more fully in renal tissues as well as retinal tissues for
dosing regimens and timing of therapies. However, given the effi-
ciency of ASO-mediated exon skipping observed in patient kidney
cells, where the next available splice acceptor is used almost ex-
clusively, this is likely to confirm that ASO treatments should be
considered as a promising therapeutic approach. It seems likely,
following on from the success of ASO-based therapy for targeting
CEP290 retinal disease, that ASO-based therapy for CEP290-
associated renal disease has true translational promise and may pro-
vide a genetic rescuing therapy for this severe ciliopathy syndrome.
In conclusion, we show that using ASO-mediated exon skip-
ping rescues a ciliary defect in patient renal epithelial cells and
can be used systemically to target CEP290 transcripts within kid-
ney tissues, offering a therapeutic approach to treating inherited
renal ciliopathies.
Materials and Methods
Study Approval. Ethical approval was obtained from the National Research
Ethics Service Committee North East (14/NE/1076), United Kingdom. All animal
experiments were conducted according to protocols approved by the Animal
Ethics Committee of Newcastle University and the HomeOffice, United Kingdom.
Statistics. All data are shown as the mean ± SEM, unless otherwise stated and
unpaired Student’s t test or one-way ANOVA followed by a Bonferroni
corrected post hoc test when comparing two or more groups. A P value of
less than 0.05 was considered statistically significant.
Clinical and DNA Sequencing. Following informed and written consent, urine
and blood sampleswere obtained froma 14-y-old boywith clinical JBTSwith a
retinal, renal, and cerebellar phenotype and a healthy gender- and age-
matched control. All methods were performed in accordance with the rel-
evant ethical guidelines and regulations.
Sequencing of Joubert syndrome genes was performed by UKGTN using
an 18 Gene Panel (Oxford Regional Genetic Laboratory Service). Confirma-
tion of mutations and segregation analysis was performed on other family
members, following informed consent, using Sanger sequencing, using exon
specific primers.
In Vitro Studies Using Human Kidney and hURECs. Immunostaining of human
kidney tissues from patients with CEP290 mutations was performed. In vitro
studies following hUREC isolation (28), culture, and ASO treatments were
performed, including immunostaining, Western blotting, and reverse
transcription-PCR and quantitative RT-PCR. Electron microscopy studies
were performed on hURECs. Please see SI Appendix for detailed materials
and methods.
In Vivo ASO Treatment of Cep290Gt/Gt Animals. In vivo studies were performed
on 28-d-old Cep290Gt/Gt animals. Renal tissues were harvested and used for
immunofluorescence studies, Western blotting, RNA extraction, and reverse
transcription-PCR and quantitative RT-PCR. Please see SI Appendix for de-
tailed materials and methods.
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